Substance P and Pain: The Neuropeptide That Amplifies It
Pain & Nociception Peptides
11 amino acids
Substance P is an 11-amino-acid neuropeptide that transmits pain signals from peripheral nerves to the spinal cord and brain through the NK1 receptor.
Munoz & Covenas, Amino Acids, 2014
Munoz & Covenas, Amino Acids, 2014
View as imageSubstance P was discovered in 1931, making it one of the oldest known neuropeptides. It took another 50 years before its role in pain transmission was established. The peptide is released from the terminals of primary afferent sensory neurons in the spinal cord dorsal horn, where it binds neurokinin-1 (NK1) receptors and amplifies nociceptive signaling.[1] Substance P does not initiate pain the way a stubbed toe or a burn does. It amplifies and sustains pain, turning acute signals into chronic states through a process called central sensitization.
This distinction matters because it explains one of pharmacology's most frustrating paradoxes: despite decades of evidence linking substance P to pain, drugs that block its receptor (NK1 antagonists) failed as analgesics in clinical trials.[2] The same drugs succeeded as anti-nausea medications (aprepitant is FDA-approved for chemotherapy-induced vomiting). Understanding why substance P blocking works for nausea but not for pain requires examining how this peptide operates at the molecular level, what happened when researchers tried to delete it, and what newer research reveals about its role in chronic pain conditions.
For related peptide analgesic approaches, see Venom-Derived Peptide Analgesics: Nature's Alternative to Opioids and Ziconotide (Prialt): The Cone Snail Venom Peptide That Treats Severe Pain.
Key Takeaways
- Substance P is an 11-amino-acid neuropeptide released from C-fiber sensory neurons in the spinal dorsal horn, where it activates NK1 receptors to amplify pain signaling (Munoz & Covenas, 2014)
- In chronic pain states, substance P drives central sensitization by upregulating NK1 receptors on dorsal horn neurons, converting temporary pain into persistent hypersensitivity (Zieglgansberger, 2019)
- Fibromyalgia patients have approximately 3-fold higher cerebrospinal fluid substance P concentrations compared to healthy controls, correlating with widespread pain severity
- NK1 receptor antagonists reverse hyperalgesia in animal models but failed as analgesics in human clinical trials, succeeding only as anti-emetics (aprepitant/Emend)
- Pain persists in mice lacking both substance P and CGRP-alpha signaling, demonstrating that these neuropeptides are not the sole drivers of nociception (MacDonald et al., 2024)
- Substance P metabolites, particularly the SP(1-7) fragment, paradoxically produce anti-nociceptive effects, opening a new therapeutic direction (Hallberg, 2018)
Molecular Structure and the Tachykinin Family
Substance P belongs to the tachykinin peptide family, which shares the C-terminal amino acid sequence Phe-X-Gly-Leu-Met-NH2. The full sequence of substance P is Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2. This 11-amino-acid peptide is encoded by the TAC1 gene (also called preprotachykinin A), which also encodes neurokinin A (NKA), another tachykinin involved in pain and inflammation.
Three tachykinin receptors exist: NK1, NK2, and NK3. Substance P binds preferentially to NK1, though it can activate NK2 and NK3 at higher concentrations. NK1 is a seven-transmembrane G-protein-coupled receptor that signals through the Gq pathway, activating phospholipase C, generating inositol trisphosphate (IP3) and diacylglycerol (DAG), raising intracellular calcium, and activating protein kinase C.[1]
Harris et al. (2022) revealed that substance P-NK1 receptor dynamics involve selective G protein signaling, meaning the cellular response depends not just on whether substance P binds NK1, but on the kinetics and duration of binding.[3] Brief exposure activates different downstream pathways than sustained exposure. This has implications for drug design: a simple on/off antagonist may not capture the nuance of how substance P actually operates at the receptor level.
Ge et al. (2025) used NMR spectroscopy to map substance P's interactions with NK1R in solution, providing the most detailed structural picture of how this peptide engages its receptor.[4] The C-terminal region of substance P makes the critical contacts for receptor activation, while the N-terminal residues influence binding affinity and receptor internalization kinetics.
How Substance P Transmits Pain
Substance P is synthesized in the cell bodies of small-diameter sensory neurons (C-fibers and some A-delta fibers) in the dorsal root ganglia. It is transported to both the peripheral terminals (in skin, joints, and viscera) and the central terminals (in the spinal cord dorsal horn). At peripheral sites, substance P contributes to neurogenic inflammation by dilating blood vessels, increasing vascular permeability, and activating mast cells. At central terminals, it modulates pain processing.
The critical pain-related action occurs in the spinal cord. When noxious stimuli activate C-fibers, substance P is released alongside glutamate into the dorsal horn. Glutamate provides the fast, immediate pain signal through AMPA and NMDA receptors. Substance P provides a slower, modulatory signal through NK1 receptors that amplifies and prolongs the pain experience.[5]
Chang et al. (2019) reviewed the ion channels involved in substance P-mediated nociception, identifying TRPV1 (the capsaicin receptor), T-type calcium channels, and ASIC (acid-sensing ion channels) as downstream mediators of substance P's pain-amplifying effects.[6] Substance P sensitizes these channels, lowering the threshold for activation so that normally non-painful stimuli begin to produce pain (allodynia) and painful stimuli produce exaggerated pain (hyperalgesia).
Central Sensitization: How Acute Pain Becomes Chronic
Central sensitization is the process by which repeated nociceptive input transforms the spinal cord from a passive relay station into an active amplifier. Substance P is a central player in this process.
Zieglgansberger (2019) published a comprehensive review in Cell and Tissue Research documenting how substance P drives pain chronicity.[2] During sustained or repeated pain, substance P release in the dorsal horn upregulates NK1 receptor expression on second-order neurons. These neurons become hyperexcitable, responding to inputs they would normally ignore. The process involves NMDA receptor potentiation (substance P removes the magnesium block from NMDA channels, allowing them to open at resting membrane potential), gene expression changes (c-Fos induction, cyclooxygenase-2 upregulation), and structural remodeling of synaptic connections.
Chen et al. (2026) extended this model with evidence that substance P/NK1 signaling in the dorsal horn activates glial cells (microglia and astrocytes), which release pro-inflammatory cytokines that further sensitize neurons.[7] This creates a positive feedback loop: substance P activates glia, glia release inflammatory mediators, inflammatory mediators sensitize neurons to release more substance P. Breaking this cycle is the theoretical rationale for targeting substance P in chronic pain.
Li et al. (2015) demonstrated that substance P spinal signaling induces glial activation and nociceptive sensitization after fracture, with NK1 receptor blockade reducing both glial markers and pain behavior in a rat model.[8] This illustrates how injury-induced substance P release can perpetuate pain well beyond the initial tissue damage.
Substance P in Chronic Pain Conditions
Substance P levels are elevated in the cerebrospinal fluid, synovial fluid, or tissue of patients with multiple chronic pain conditions. Lisowska et al. (2015) measured substance P in patients with chronic connective tissue inflammation and found consistently elevated levels correlating with pain severity and inflammatory markers.[9]
Fibromyalgia: Four independent studies have reported approximately 3-fold elevations of cerebrospinal fluid substance P in fibromyalgia patients compared to healthy controls. These elevations correlate with pain sensitivity, fatigue, and sleep disruption. Substance P-driven central sensitization is a leading mechanistic hypothesis for fibromyalgia's widespread pain.
Osteoarthritis: Warner et al. (2017) found that variation in the NK1/substance P receptor gene (TACR1) was associated with pain severity in knee osteoarthritis, suggesting genetic variation in substance P signaling contributes to why some patients experience more pain than others with similar joint damage.[10]
Intervertebral disc disease: He et al. (2020) showed that substance P expression in degenerated intervertebral discs drives discogenic pain by promoting angiogenesis and nerve ingrowth into normally avascular disc tissue.[11] The peptide literally recruits blood vessels and nerves into the damaged disc, creating new pain pathways that did not exist before the injury.
Migraine: Substance P and CGRP (calcitonin gene-related peptide) are co-released from trigeminal sensory neurons during migraine attacks. Pellesi et al. (2025) revisited substance P's role in migraine in light of the clinical success of anti-CGRP drugs, arguing that substance P measurement methodology in earlier studies may have led to underestimation of its contribution.[12] The contrast between the two peptides is instructive: anti-CGRP drugs succeeded where anti-substance P drugs failed, suggesting CGRP plays a more dominant role in migraine-specific pain. For the full story, see CGRP and Migraines: The Peptide Discovery That Revolutionized Headache Treatment and CGRP Antagonists Explained: How Anti-CGRP Drugs Stop Migraines.
Complex regional pain syndrome (CRPS): Konig et al. (2022) investigated substance P serum degradation in CRPS patients, finding altered enzymatic processing of the peptide that resulted in abnormal substance P fragment profiles. This suggests that pain pathology involves not just substance P levels but the balance between intact peptide and its metabolites.
Dental pain: Sacerdote and Bhatt (2012) reviewed the role of substance P in dental pain mechanisms, documenting how tooth pulp inflammation triggers massive substance P release from trigeminal afferents, contributing to the intense pain characteristic of pulpitis.[1] The dental pain model has been extensively used in NK1 antagonist clinical trials, consistently showing failure to achieve analgesia.
The NK1 Antagonist Paradox: Why Blocking Substance P Failed
The preclinical case for NK1 receptor antagonists as analgesics was overwhelming. Animal studies consistently showed that blocking NK1 reduced inflammatory pain, neuropathic pain, and visceral pain. Iadarola et al. (2017) even demonstrated that selectively destroying NK1-expressing neurons in the spinal cord using a bioengineered substance P-saporin conjugate produced profound analgesia in animals.[13]
Yet clinical trials of NK1 antagonists (MK-869, L-733,060, aprepitant, and others) as painkillers in humans produced negative results. Patients with dental pain, neuropathic pain, migraine, and osteoarthritis showed no meaningful improvement over placebo.
Several explanations have been proposed:
Redundancy in pain signaling. MacDonald et al. (2024) published a landmark study showing that pain persists in mice genetically engineered to lack both substance P and CGRP-alpha signaling simultaneously.[14] If eliminating two major nociceptive neuropeptides does not abolish pain, blocking one receptor pharmacologically is unlikely to produce analgesia. Pain is transmitted through multiple parallel pathways (glutamate, ATP, bradykinin, prostaglandins, nerve growth factor), and substance P is one voice in a loud chorus.
Substance P amplifies, but does not initiate. NK1 receptor antagonists are effective at reversing hyperalgesia (exaggerated pain) in sensitized states but leave acute pain unchanged. Most clinical trials tested NK1 antagonists against acute pain models (dental extraction, postoperative pain), where substance P's amplifying role is less prominent than glutamate-driven fast transmission.
Species differences in NK1 receptor pharmacology. The binding affinity of NK1 antagonists differs between rodent and human NK1 receptors. Drugs that fully occupy rodent NK1 receptors may achieve only partial occupancy of human receptors at tolerable doses.
Successful anti-emesis provides a clue. Aprepitant (Emend) is FDA-approved for chemotherapy-induced nausea and vomiting, where NK1 receptors in the brainstem nucleus tractus solitarius mediate the emetic reflex. In this circuit, substance P/NK1 is a dominant signal rather than a redundant one. The drug works where substance P is essential and fails where it is merely contributory.
The Substance P Metabolite Surprise
An unexpected direction emerged when researchers discovered that substance P breakdown products have biological activity of their own, and in some cases the opposite activity of intact substance P.
Hallberg (2018) reviewed work on SP(1-7), the N-terminal heptapeptide fragment produced when substance P is cleaved by endopeptidases.[15] This fragment does not bind NK1 receptors. Instead, it produces anti-nociceptive effects through a mechanism that appears to involve opioid receptor modulation. In animal models, SP(1-7) and small-molecule peptidomimetics designed to mimic it reduced neuropathic pain behavior.
Kriska et al. (2024) showed that cellular metabolism of substance P produces multiple NK1 receptor agonist fragments with different potencies and signaling profiles, suggesting that substance P's actions in vivo are more nuanced than simple NK1 receptor activation.[16] The intact peptide and its fragments may produce a spectrum of effects from pro-nociceptive to anti-nociceptive depending on the local enzymatic environment.
This raises an intriguing possibility: rather than blocking substance P signaling entirely (which failed as analgesia), promoting its cleavage to anti-nociceptive fragments or designing drugs that mimic SP(1-7) could provide pain relief through a completely different mechanism. See Peptide Approaches to Neuropathic Pain: Targeting the Source for more on peptide-based pain therapies.
Substance P Beyond Pain
While this article focuses on pain, substance P has roles throughout the body that are worth noting because they create therapeutic trade-offs when targeting the NK1 receptor.
Wound healing: Substance P promotes wound repair by stimulating angiogenesis, recruiting immune cells, and modulating macrophage polarization toward a reparative phenotype.[17] Leal et al. (2015) showed that substance P promotes wound healing in diabetes by modulating inflammation, suggesting that chronic suppression of substance P could impair tissue repair.
Inflammation: Zhu et al. (2023) reviewed substance P's role in inflammation and organ injury across multiple organ systems, documenting how the peptide activates NF-kB signaling, promotes cytokine release from macrophages and mast cells, and contributes to neurogenic inflammation in the skin, joints, gut, and lungs.[18]
Neuropsychiatry: Substance P and NK1 receptors are expressed in brain regions involved in stress, anxiety, and depression (amygdala, hypothalamus, locus coeruleus). NK1 antagonists showed initial promise as antidepressants in a 1998 trial that generated widespread excitement, though subsequent larger trials produced mixed results. See Neuropeptides and Depression: The Biology Beyond Serotonin for this evidence.
Immune regulation: Substance P modulates T cell function, macrophage activation, and mast cell degranulation. Its role in pain is inseparable from its role in immune-mediated inflammation, which is why conditions like rheumatoid arthritis and inflammatory bowel disease involve both elevated substance P and elevated pain.
For the related endogenous opioid peptide system that counterbalances substance P, see Beta-Endorphin: The Runner's High Peptide and Dynorphin and the Kappa Receptor: The "Dark Side" of Opioid Peptides.
Current Research Directions
The field has moved past simple NK1 receptor blockade toward more nuanced approaches.
Biased agonism/antagonism: Harris et al. (2022) showed that NK1 receptor signaling is pathway-selective, meaning future drugs could block pain-related signaling while preserving other NK1 functions.[3]
SP(1-7) peptidomimetics: Small-molecule mimics of the anti-nociceptive substance P fragment are in preclinical development, offering a drug class that exploits substance P biology rather than opposing it.
Spinal NK1 neuron ablation: Iadarola et al. (2017) demonstrated that destroying NK1-expressing neurons in the spinal cord with substance P-saporin conjugates produces lasting analgesia without affecting acute pain sensation.[13] This approach is in early clinical investigation for intractable pain conditions.
Substance P as a biomarker: Elevated CSF substance P may serve as a diagnostic biomarker for central sensitization in conditions like fibromyalgia, helping to identify patients who would benefit from centrally-acting therapies rather than peripheral anti-inflammatory drugs.
Combination approaches: The MacDonald et al. (2024) finding that pain persists without both substance P and CGRP suggests that effective peptide-based analgesia may require targeting multiple neuropeptide pathways simultaneously. Venom-derived peptides that act on ion channels rather than neuropeptide receptors represent a distinct approach that bypasses this redundancy problem entirely. See Conotoxins: How Venomous Snails Are Advancing Pain Medicine for how omega-conotoxins block calcium channels that substance P uses for vesicular release, providing analgesia through a mechanism that is upstream of the neuropeptide redundancy problem.
Substance P and the Neuroinflammation Cycle
One dimension that deserves emphasis is how substance P bridges the gap between the nervous system and the immune system in pain pathology. This neuro-immune interface is central to chronic pain and explains why substance P elevation correlates with both pain intensity and inflammatory markers.
When substance P is released from peripheral nerve terminals, it binds NK1 receptors on mast cells, triggering degranulation and release of histamine, prostaglandins, and pro-inflammatory cytokines. The histamine released by mast cells, in turn, stimulates more substance P release from sensory nerve endings, creating a bidirectional amplification loop. Suvas (2017) documented this cycle across multiple tissue types, showing that substance P-mast cell interactions drive neurogenic inflammation in skin, joints, and the gastrointestinal tract.[5]
In the central nervous system, substance P activates microglia and astrocytes through NK1 receptors expressed on these glial cells. Activated glia release TNF-alpha, IL-1-beta, and IL-6, which sensitize nearby neurons and lower their threshold for firing. This glial-neuronal interaction sustains pain long after the initial tissue injury has healed. It is the biological substrate of the transition from acute to chronic pain, and substance P is the molecular signal that initiates the glial response.
The neuroinflammation cycle also explains the association between substance P and depression, anxiety, and stress. The same brain regions that process pain (anterior cingulate cortex, insula, prefrontal cortex) also process emotional suffering, and substance P/NK1 signaling modulates activity in all of them. Patients with chronic pain and comorbid depression often have elevated substance P in both the spinal cord and the brain, suggesting a shared neuropeptide mechanism underlying both conditions.
The Bottom Line
Substance P is the neuropeptide most associated with pain amplification in the spinal cord, driving central sensitization through NK1 receptor activation, glial cell recruitment, and NMDA receptor potentiation. Its role in chronic pain conditions like fibromyalgia, osteoarthritis, and migraine is well documented. The failure of NK1 antagonists as analgesics, despite overwhelming preclinical evidence, revealed that pain signaling is redundantly encoded and that substance P amplifies rather than initiates nociception. The discovery that substance P metabolites like SP(1-7) produce anti-nociceptive effects has opened a new therapeutic direction: exploiting substance P biology rather than simply blocking it.